【摘要】 目的探究肝细胞癌(HCC)患者癌组织中金属硫蛋白-3 (metallothionein-3,MT-3)水平与TACE治疗疗效的关系。方法选择2013年3月至2015年1月104例确诊的HCC患者作为研究对象。采用蛋白质免疫印迹法(Western blotting)检测HCC组织中MT-3水平,并分析其评价TACE治疗近、远期疗效的价值。结果有效组HCC组织中MT-3水平高于无效组,差异有统计学意义(P<0.05)。MT-3评价接受TACE治疗的HCC患者近期疗效的受试者工作特征(ROC)曲线下面积(AUC)、灵敏度和特异度分别为0.825、76.5%和78.6%。MT-3评价接受TACE治疗的HCC患者远期疗效的ROC曲线AUC、灵敏度和特异度分别为0.913、88.10%和83.87%。Cox回归分析结果显示肿瘤分期、Child-Pugh分级和肿瘤直径是HCC患者5年生存预后的独立危险因素(P<0.05),MT-3是HCC患者5年生存预后的独立保护因素(P<0.05)。结论 MT-3评价接受TACE治疗的HCC患者近、远期疗效的价值均较高,可辅助判断生存预后。更多还原

【Abstract】 Objective To investigate the correlation between the metallothionein-3(MT-3) level in cancer tissues and the therapeutic effect of transcatheter arterial chemoembolization(TACE) in patients with hepatocellular carcinoma(HCC). Methods A total of 104 patients with HCC, whose diagnoses were confirmed at the Lanzhou Municipal Second People’s Hospital of China during the period from March 2013 to January 2015, were enrolled in this study. Western blotting was used to detect the level of MT-3 in HCC tissues, and its value in assessing the short-term and long-term efficacy of TACE treatment was analyzed.Results The level of MT-3 in HCC tissues in the effective group was higher than that in the ineffective group,and the difference was statistically significant(P<0.05). The area under the receiver operating characteristic(ROC) curve(AUC), sensitivity and specificity of MT-3 for evaluation of the short-term efficacy of HCC patients after receiving TACE were 0.825, 76.5% and 78.6%, respectively. The AUC of ROC, sensitivity and specificity of MT-3 in evaluating the long-term efficacy of HCC patients after receiving TACE were 0.913, 88.10%and 83.87%, respectively. Cox regression analysis showed that tumor stage, Child-Pugh classification and tumor diameter were independent risk factors for 5-year survival prognosis of patients with HCC(P<0.05), and MT-3 level was an independent protective factor for 5-year survival prognosis of HCC patients(P <0.05).Conclusion MT-3 level carries higher value in assessing the short-term and long-term efficacy in HCC patients after receiving TACE, which can be used to make adjuvant judgment of survival prognosis.更多还原